Ipsen S.A. (EPA: IPN)
France
· Delayed Price · Currency is EUR | Market Cap | 8.88B |
| Revenue (ttm) | 3.44B |
| Net Income (ttm) | 681.20M |
| Shares Out | 82.20M |
| EPS (ttm) | 8.15 |
| PE Ratio | 13.60 |
| Forward PE | 10.89 |
| Dividend | 1.20 (1.11%) |
| Ex-Dividend Date | n/a |
| Volume | 178,686 |
| Open | 107.20 |
| Previous Close | 107.90 |
| Day's Range | 105.30 - 108.00 |
| 52-Week Range | 99.70 - 126.70 |
| Beta | 0.60 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 13, 2025 |
About Ipsen
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical t... [Read more]
Full Company ProfileFinancial Performance
In 2023, Ipsen's revenue was 3.31 billion, an increase of 4.75% compared to the previous year's 3.16 billion. Earnings were 644.40 million, a decrease of -0.65%.
Financial StatementsNews
Genfit Balances Ipsen Partnership With High-Risk Pipeline Ambitions
Genfit licensed Iqirvo's global rights to Ipsen in 2021, securing milestone payments and royalties. Read why GNFT stock's long-term prospects remain uncertain.
Ipsen S.A. reports Q3 results; raises FY24 guidance
Ipsen S.A. press release (IPSEY): Q3 Revenue of €836.6M (+8.3% Y/Y). Full-year 2024 guidance: Based on the strong performance in the third quarter, Ipsen has further increased
Eton Pharmaceuticals to buy Increlex product from Ipsen
Expert financial writer providing valuable insights on investment strategies, market trends, and personal finance tips for readers.
Ipsen's Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease
Kayfanda ® (odevixibat) approved as new treatment choice for cholestatic pruritus in children from six months with the rare liver condition, Alagille Syndrome E.U. marketing authorization for Kayfanda...
Ipsen's Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade
European Commission grants conditional marketing authorization for Iqirvo ® (elafibranor), first-in-class new treatment for primary biliary cholangitis (PBC), a rare liver disease Approval follows pos...
Employee of French drugmaker Ipsen to plead guilty to US insider trading
An employee of French drugmaker Ipsen has agreed to plead guilty to illegally making more than $262,000 by trading on inside information he learned about his company's plans to acquire cancer drug dev...
Ipsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024)
Ipsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024) Attachment 2024 Ipsen Half-Year Financial Report
Annual General Meeting of Ipsen S.A. held on 28 May 2024
PARIS, FRANCE, 28 May 2024 - The Annual General Meeting of Ipsen S.A. (Euronext: IPN; ADR: IPSEY) was held today at the Salons de l'Hôtel des Arts et Métiers, 9 bis, avenue d'Iéna, 75116 Paris (France...
Description of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at Ipsen S.A.'s Annual General Meeting on 28 May 2024
PARIS, FRANCE, 28 May 2024 - In accordance with the provisions of Article L.22-10-62 et seq. of the French Commercial Code, the European Regulation (EU) No 596/2014 of the European Parliament and of t...
Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2024 Annual General Meeting
Information relating to the holding of the Combined Shareholders' Meeting of 28 May 2024 of Ipsen S.A. Formalities for making available and consulting preparatory documents to the Meeting BOULOGNE-BIL...
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
PARIS, FRANCE, 24 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024.
Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors
Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors
2 More Potential Biotech Buyout Targets
M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related produ...
Ipsen S.A. publishes its 2023 Consolidated Financial Statements
Ipsen S.A. - 2023 Consolidated Financial Statements Attachment Ipsen - 2023 Consolidated Financial Statements
US FDA approves Ipsen's rare bone disorder drug
The U.S. Food and Drug Administration on Wednesday approved French drugmaker Ipsen's bone disorder drug, making it the first treatment available to patients with the rare condition that causes abnorma...
US FDA approves Ipsen's SohonosTM (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva
PARIS, FRANCE, 16 August 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today approval by the U.S. Food and Drug Administration (FDA) of Sohonos™ (palovarotene) capsules as a retinoid indicated fo...
Ipsen S.A. publishes its 2023 Half-Year Financial Report
Ipsen S.A. publishes its 2023 Half-Year Financial Report Attachment 2023 Half-year Financial Report
Ipsen SA initiates a share buy-back program to cover its free employee share-allocation plan
REGULATED INFORMATION Ipsen initiates a share buy-back program to cover its free employee share-allocation plan Paris (France), 1 June 202 3 - Ipsen (Euronext: IPN; ADR: IPSEY) has appointed an invest...
Ipsen S.A. - Combined Shareholders' Meeting of Ipsen S.A. held on 31 May 2023
REGULATED INFORMATION COMBINED SHAREHOLDERS' MEETING OF IPSEN S.A. HELD ON 31 MAY 2023 ALL THE RESOLUTIONS SUBMITTED TO THE SHAREHOLDERS' VOTE HAVE BEEN APPROVED Paris (France), 31 May 2023 – The Com...
Ipsen delivers a strong sales performance in the first quarter of 2022
Ipsen delivers a strong sales performance in the first quarter of 2022 Paris (France), 27 April 2022 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, publishes i...
Ipsen S.A. publishes its 2022 Universal registration document
Paris (France), 6 April 2023 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, announced today that its 2022 Universal Registration Document has been filed with t...
Ipsen S.A. (IPSEY) Q4 2022 Earnings Call Transcript
Ipsen S.A. (OTCPK:IPSEY) Q4 2022 Results Conference Call February 9, 2023 7:45 AM ET Company Participants David Loew - CEO Aymeric Le Chatelier - CFO Howard Mayer - Head, Research and Development Conf...
Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde® Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI
Investigational Onivyde® (irinotecan liposome injection) in the NALIRIFOX treatment regimen demonstrated statistically significant improvements in overall survival and progression-free survival compar...
SHAREHOLDER ALERT: Weiss Law Investigates Albireo Pharma, Inc.
NEW YORK , Jan. 9, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Albireo Pharma, Inc. ("Albireo" or the "...
Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
PARIS--(BUSINESS WIRE)--Regulatory News: Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) announced the Ipsen (Euronext: IPN; ADR: IPSEY) anno...